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Summary
A chemical genetics approach identified a cellular target of several proapoptotic farnesyl transferase inhibitors (FTIs).
Treatment with these FTIs caused p53-independent apoptosis in Caenorhabditis elegans, which was mimicked by knock-
down of endosomal trafficking proteins, including Rab5, Rab7, the HOPS complex, and notably the enzyme Rab geranyl-
geranyl transferase (RabGGT). These FTIs were found to inhibit mammalian RabGGT with potencies that correlated with
their proapoptotic activity. Knockdown of RabGGT induced apoptosis in mammalian cancer cell lines, and both RabGGT
subunits were overexpressed in several tumor tissues. These findings validate RabGGT, and by extension endosomal
function, as a therapeutically relevant target for modulation of apoptosis, and enhance our understanding of the mecha-
nism of action of FTIs.S I G N I F I C A N C E
FTIs were designed to treat tumors by inhibiting the function of the farnesyl transferase (FT) substrate Ras; however, they have activity
on cancer cells and tumors that do not contain activated Ras, suggesting additional mechanisms. Using a chemical genetics
approach, we have identified the enzyme RabGGT as an additional direct target of several proapoptotic FTIs, and demonstrated
that loss of RabGGT function triggers p53-independent apoptosis. These findings will impact the interpretation of in vivo efficacy and
toxicity studies of clinical FTIs, and may facilitate patient selection. Our results also point to the development of a new generation
of anticancer agents specifically targeting RabGGT.Introduction
Modern target-based drug discovery begins with the develop-
ment of highly potent in vitro agonists or antagonists of a dis-
ease-associated target. However, agents that appear to have
exquisite specificity for their target often yield unexpected bio-
logical activities. For example, compounds inhibiting farnesyl
transferase (FT) have been developed as anticancer agents on
the premise that they should block transforming Ras activity
by inhibiting Ras prenylation and membrane association. While
the FTIs have shown promise in the clinic, the heterogeneity of
responses seen in vivo and lack of correlation to Ras function
suggests several mechanisms of therapeutic action (reviewed
by Head and Johnston, 2003). The role of other proteins that
require farnesylation has come under increasing scrutiny
(Prendergast and Rane, 2001). However, the potential role of
other direct molecular targets of the compounds has not re-
ceived widespread attention.
Eukaryotic cells possess two other prenyl transferases, gera-
nylgeranyl transferase I (GGTI) and Rab geranylgeranyl trans-
ferase (RabGGT or GGTII). FT and GGTI are the most closelyCANCER CELL : APRIL 2005 · VOL. 7 · COPYRIGHT © 2005 ELSEVIER INCrelated, sharing a common α subunit and 30% identity in their
β subunits. FT and GGTI (known as the CaaX prenylases) both
recognize the tetrapeptide motif CaaX at the C terminus of their
substrates and modify a single cysteine residue. Their sub-
strates are then further processed by the CaaX endoprotease
and the isoprenylcysteine carboxyl methyltransferase (ICMT)
(Clarke, 1992). Since GGTI modifies essential cellular proteins
such as the Rho family of GTPases (Bishop and Hall, 2000),
the development of FTIs has focused on selectivity for FT over
GGTI (for example, see Bell et al., 2002; Hunt et al., 2000).
In contrast, the third eukaryotic protein prenylase RabGGT
appeared so distinct from the CaaX prenylases that its poten-
tial for interaction with the therapeutic FTIs was considered to
be low. Like FT and GGTI, RabGGT functions as a heterodimer.
The α subunit has 27% identity to that of the CaaX prenylases
but contains additional domains, while the β subunit shows
29% identity to that of FT. The protein substrates of RabGGT
have heterogeneous C termini that usually contain two cysteine
residues (CXC), both of which are modified by geranylgeranyl
groups without any subsequent processing steps. Unlike the
CaaX prenylases, RabGGT requires specific accessory pro-. DOI 10.1016/j.ccr.2005.03.024 325
A R T I C L Eteins known as REPs to guide the interaction with its targets
(reviewed by Seabra, 2000). Despite these differences, the
three prenylases have strikingly similar active sites (Strickland
et al., 1998; Zhang et al., 2000) and mechanisms of substrate
modification (Long et al., 2002). The RabGGT substrates iden-
tified to date are all members of a family of >60 Ras-related
proteins called Rabs. These monomeric GTPases regulate in-
tracellular membrane traffic, and their prenylation is usually
essential for correct targeting and function (reviewed by De-
neka et al., 2003). New work linking levels of Rab25 to the
aggressiveness of epithelial cancers is the first direct evidence
that they play an important role in carcinogenesis (Cheng et
al., 2004).
During the development of small molecule FTIs at Bristol-
Myers Squibb, several compounds were observed to possess
a proapoptotic activity that did not correlate with their potency
against either FT or GGTI (Rose et al., 2001). Using the nema-
tode Caenorhabditis elegans, we undertook a chemical genet-
ics approach to clarify their mechanism of action. These FTIs
were found to be proapoptotic in C. elegans, which is a well-
validated system for studying apoptosis (reviewed by Gartner
et al., 2000; Stergiou and Hengartner, 2004). Similar proapo-
ptotic effects were produced in C. elegans by targeted knock-
down of components of the RabGGT complex and specific
members of the Rab family. Additional biochemical and genetic
tests established that the proapoptotic activity of these com-
pounds in nematodes and in human cancer cells is related to
their inhibition of RabGGT, and implicated this enzyme for the
first time in cancer and apoptosis.
Results
Proapoptotic activity of FT inhibitors in C. elegans
As germ cells in C. elegans progress through meiosis and dif-
ferentiation to become mature oocytes, some cells undergo
programmed cell death (apoptosis) as part of normal develop-
ment (Gumienny et al., 1999). Although up to 300 oocytes may
undergo apoptosis over the life of the animal, the cell corpses
are rarely seen in wild-type worms. Since germ cells are com-
petent to undergo apoptosis and can be visualized in an intact
animal, the number of corpses provides a sensitive and accu-
rate indicator for apoptotic modulators.
Four BMS compounds with similar levels of FT inhibition but
differing potencies in a mammalian apoptosis assay (Table 1;
assays as described by Rose et al. [2001]) were selected for
evaluation for the phenotype of apoptosis in C. elegans germ-
line cells. Worms treated with compound BMS1 showed a
striking increase in the number of cell corpses (Figures 1A andTable 1. Activity of compounds in enzyme inhibition assays and in cellular assays for apoptosis and reversion
Rat1-CVLS (H-Ras): HCT116 apoptosis
Compound FT IC50 (nM) % reversion at 100 nM (EC50, M) C. elegans apoptosis RabGGT IC50 (nM) RabGGT IC90 (nM)
BMS1 7.8 30 ++ (0.4) ++ 21 200
BMS2 2.4 75 + (3.3) + 36 295
BMS3 1.4 90 ++ (0.04) + 16 93
BMS4 1.5 85 +/− (30) − 540 10 M3261B). While untreated wild-type adult worms contained at most
two apoptotic corpses/gonad, with an average of less than
one, worms treated with BMS1 at 0.8 mM had at least two
corpses and an average of over six (Table 2A). The effect of
BMS1 was similar in degree and appearance to that of RNA
interference (RNAi) directed against ced-9, a C. elegans homo-
log of the antiapoptotic protein Bcl-2 (Table 2A). The relatively
high dose of compound required is consistent with other
studies (R.M.K., unpublished; Lewis et al., 1980), and may be
due to the worm’s protective cuticle. Induction of apoptosis by
BMS1 was dose-dependent (Supplemental Figure S1). Com-
pounds BMS2 and BMS3 were also found to increase the level
of germline apoptosis, whereas BMS4 had a very minor effect
(Figure 2A; Table 2A). Thus, the observations from a mamma-
lian cellular apoptosis assay were recapitulated in the C. ele-
gans assay. This correlation persisted for a further series of 8Figure 1. Germline cell apoptosis in C. elegans
Nomarski images of the gonad arm region in a one- to two-day-old worm,
oriented with the distal region of the gonad to the top. Germ cells proceed
in a clockwise direction as they mature. White arrowheads indicate exam-
ples of an apoptotic corpse.
A: Wild-type worm, treated with DMSO. No corpses are visible.
B: Wild-type worm, exposed to BMS1 (1.6 mM) for 16 hr. Several corpses
are present in the distal region.
C: ced-1(e1735); ced-10 (n1993) engulfment mutant worm. A group of de-
generating corpses is present in the proximal gonad region.
D: vps-41(ep402) mutant worm. A large cluster of corpses is present in the
distal region.CANCER CELL : APRIL 2005
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Host strain Protein name/ORF targeted by RNAi treatment Compound (dose) Mean corpses (SD)
A WT Vehicle 1.1 (0.8)
WT BMS1 (0.8 mM) 6.9 (2.8)
WT BMS2 (1.6 mM) 2.0 (1.4)
WT BMS3 (1.6 mM) 2.3 (1.6)
WT BMS4 (1.6 mM) 1.2 (1.2)
WT CED-9/T07C4.8 4.8 (2.4)
B WT Vehicle 0.4 (0.8)
WT BMS1 (1.6 mM) 6.3 (1.3)
cep-1 BMS1 (1.6 mM) 5.3 (1.8)
ced-3 Vehicle 0.1 (0.4)
ced-3 BMS1 (1.6 mM) 0.1 (0.3)
ced-4 Vehicle 0.0 (0.0)
ced-4 BMS1 (1.6 mM) 0.2 (0.4)
C cep-1 mock 0.6 (0.8)
cep-1 VPS-11/R06F6.2 22.0 (8.5)
cep-1 VPS-16/C05D11.2 15.1 (6.3)
cep-1 VPS-18/W06B4.3 15.3 (4.4)
cep-1 VPS-33/Y75B8A.24 5.3 (2.0)
cep-1 VPS-39/T08G5.5 10.1 (5.1)
cep-1 RAB-5/F26H9.6 10.9 (4.0)
cep-1 RAB-7/W03C9.3 18.2 (6.4)
cep-1 RAB-18/Y92C3B.3 1.0 (0.7)
D cep-1 RabGGT-α/M57.2 5.5 (2.7)
cep-1 RabGGT-β/B0280.1 16.9 (6.4)
cep-1 Rab GDI/Y57G11C.10 13.6 (6.0)
cep-1 FT-α/GGT1-α/R02D3.5 2.6 (1.6)
cep-1 FT-β/R23B12.6 1.6 (0.8)
cep-1 GGT1-β/Y48E1B.3 0.9 (1.1)
cep-1 CaaX protease/C04F12.1 1.2 (0.9)
cep-1 ICMT/F21F3.3 0.7 (0.8)
E WT Vehicle 0.7 (0.7)
WT BMS1 (0.3 mM) 2.3 (1.8)
WT RabGGT-α/M57.2 Vehicle 2.7 (1.5)
WT RabGGT-α/M57.2 BMS1 (0.3 mM) 8 (3.0)
WT Control ORF Vehicle 2.8 (2.0)
WT Control ORF BMS1 (0.3 mM) 2.1 (1.3)Figure 2. Effect of compound treatment and
RNAi on levels of apoptosis in C. elegans germ-
line cells
Each column shows percentage of worms in the
sample population that contained two or fewer
corpses (black), three or four corpses (gray), or
more than four corpses (white). Values were de-
rived from representative experiments using 10–
24 animals per treatment.
A: Wild-type worms treated for 16 hr with com-
pounds BMS1 through BMS4 at 0.8 mM.
B: cep-1(ep347) mutant worms were treated
with RNAi directed against mRNA for RAB-7 or
the RabGGT subunits or FT-β, as indicated.
C: Wild-type worms were treated with com-
pound BMS1 at 0.3 mM, or RNAi against
RabGGT-α, or both. The effects of the com-
bined treatment are more than the additive ef-
fects of each individual treatment. The effect of
RNAi against an unrelated target, both alone
and in combination with BMS1, is also shown.CANCER CELL : APRIL 2005 327
A R T I C L EFTI compounds (data not shown), indicating that the cause of
apoptosis was mechanistically related in the two species.
Proapoptotic effects are p53-independent
but require a functional caspase pathway
In addition to developmentally programmed apoptosis, germ
cells in C. elegans can undergo DNA damage-induced apopto-
sis through a conserved checkpoint pathway that requires p53
function (Derry et al., 2001; Gartner et al., 2000; Schumacher
et al., 2001). No reduction of the proapoptotic effect of BMS1
was observed upon treatment of a p53 deletion (cep-1) mutant
strain of C. elegans (Table 2B), indicating that the compound
action was p53-independent.
To investigate whether the apoptotic effects of the BMS
compounds in C. elegans were mediated via the canonical cas-
pase pathway, compound BMS1 was applied to worms carry-
ing mutations in either ced-3 (caspase) or ced-4 (APAF1). While
treatment of wild-type worms with BMS1 increased the num-
ber of corpses to an average of over six per arm, no increase
in corpses was observed when the ced-3 or ced-4 mutants
were treated (Table 2B). This suggests that the corpses ob-
served in BMS1-treated worms were derived via the estab-
lished apoptotic mechanism.
An observed increase in apoptotic corpses could be due to
either a defect in the apoptosis process itself or to a failure to
engulf and clear the apoptotic corpses from the gonad (re-
viewed by Hengartner, 2001). We examined the gonad arm re-
gion in a worm strain carrying both the ced-1 and ced-10 mu-
tations, leading to absence of engulfment. The corpses in this
strain showed a characteristic vacuolated morphology that
was distinct from that of corpses produced by RNAi against
ced-9 (Bcl-2), and they accumulated in the proximal region of
the gonad arm (Figure 1C), where they persisted indefinitely.
Since the corpses in BMS compound-treated worms were not
concentrated in the distal region and did not appear vacuo-
lated (Figure 1B), and disappeared over time (data not shown),
the compound-induced increase in the number of corpses was
likely due to an increase in apoptosis per se, rather than a fail-
ure to engulf the corpses that arise.
Genetic screens implicate Rab Proteins
and RabGGT in apoptosis
In parallel with our studies using compounds, EMS mutagene-
sis and RNA interference (RNAi) screens were conducted to
identify key mediators of germline apoptosis in C. elegans.
Since we were interested in regulators that act in the absence
of a functional p53 protein (which is mutated in many cancers;
Slee et al., 2004), we looked for genes whose inactivation re-
sulted in an increase in the number of apoptotic cells in a cep-1
deletion mutant.
In a forward genetic approach, approximately 58,000 F2 and
100,000 F1 EMS-mutagenized genomes were screened, and
four loci were identified. For the mutant that showed the
strongest increase in germline apoptosis, ep402, adults typi-
cally displayed >20 apoptotic corpses per gonad arm (Figure
1D). ep402 also caused phenotypes not associated with apo-
ptosis, including maternal-effect embryonic lethality and par-
tially penetrant larval arrest. The increased apoptosis in the
ep402 mutant was p53-independent, but was blocked by a
ced-4/APAF1 loss-of-function mutation (data not shown). Mo-
lecular genetic analysis revealed that the predicted genes328Y34B4A.1 and F32A6.3 were in fact a single locus, which we
named vps-41, that was affected by the ep402 mutation. vps-
41 encodes a 901 amino acid protein that is orthologous to
yeast Vps41 (29% identical and 54% similar over 179 amino
acids) and human VPS41 (28% identical and 50% similar over
842 amino acids). In Saccharomyces cerevisiae, Vps41 is re-
quired for sorting of proteins to the vacuole/lysosome, specifi-
cally for the step of endosomes and autophagosomes docking
to lysosomes prior to vesicle fusion (Nakamura et al., 1997).
C. elegans VPS-41 contains both the clathrin heavy chain re-
peat and the RING-H2 zinc finger domains present in human
VPS41. The ep402 allele was found to be a nonsense mutation
that truncated both these domains.
In addition to the forward-genetic approach, RNAi treatment
was used to screen for genes for which a reduction of function
caused an increase in germline apoptosis in a cep-1 deletion
background. We used a focused set of RNAi reagents compris-
ing 2,636 genes that included the majority of kinases, phos-
phatases, proteases, and nonolfactory G protein-coupled re-
ceptors encoded in the C. elegans genome. Since we had
identified the C. elegans homolog of VPS41 in the previous
screen, indicating that endosome-lysosome protein sorting or
autophagy (degradation of cytoplasmic proteins and organ-
elles) may play a role in apoptosis, we also screened RNAi rea-
gents for a set of 70 C. elegans genes that were related to
genes implicated in lysosomal trafficking and/or autophagy in
yeast. From this panel of 2706 genes, we identified 18 genes
for which RNAi knockdown resulted in elevated levels of germ-
line apoptosis. Several of these genes will be described else-
where. Although the effect of the RNAi treatment varied in pen-
etrance and expressivity from gene to gene, in each case, the
proapoptotic effects were seen in both wild-type and p53 mu-
tant backgrounds, and were ced-3/caspase- and ced-4/
APAF1-dependent (data not shown). Because apoptotic regu-
lators of interest were to be validated in a mammalian cell-
autonomous system (as shown in Figure 4), they were not rig-
orously tested for effects on the C. elegans-specific engulfment
and disposal pathways. However, in each case, it was ob-
served that the phenotype did not resemble existing engulf-
ment mutants (compare Figures 1C and 1D).
Among the genes that most strongly induced apoptosis in
this RNAi knockdown screen, we noted orthologs encoding the
five proteins (Vps11, Vps16, Vps18, Vps33, Vps39; Table 2C)
that combine with Vps41 to form the HOPS complex in yeast.
The HOPS complex interacts with the GTPase Rab7, and to-
gether they are required to drive endosome-lysosome and au-
tophagosome-lysosome docking and fusion (Seals et al.,
2000). Inactivation of the C. elegans ortholog of RAB7, rab-7,
also led to high levels of germline apoptosis (Table 2C). How-
ever, RNAi of homologs of yeast autophagy-specific genes did
not induce germline apoptosis, suggesting that endosome-
lysosome function was of primary relevance. We examined the
effect of inactivating the 28 other Rab family members iden-
tified in the C. elegans genome. Only RNAi of rab-7 and rab-5
(the single C. elegans ortholog of the human RAB5A, RAB5B,
and RAB5C genes) was found to induce germline apoptosis
(Table 2C). Rab5 and Rab7 share a function in protein traffick-
ing from early endosomes to late endosomes. RNAi against
the single C. elegans ortholog of the mammalian Rab guanine
nucleotide dissociation inhibitors GDI1 and GDI2, which are
positive regulators of Rab function, also induced high levels ofCANCER CELL : APRIL 2005
A R T I C L Egermline apoptosis (Table 2D). Next, we examined inactivation
of the enzyme responsible for prenylation of the Rab GTPases.
RNAi directed against mRNA for either the C. elegans
RabGGT-α or RabGGT-β subunit was effective at inducing
germline apoptosis. In contrast, RNAi treatment directed
against C. elegans genes encoding either the FT-β or GGTI-β
subunit, the α subunit shared by FT and GGTI, or other compo-
nents of the CaaX processing system, did not result in in-
creased apoptosis in this assay (Table 2D). The finding that a
reduction of RabGGT expression caused increased apoptosis,
in conjunction with the known functional and structural similari-
ties between this enzyme and FT, led us to consider that
RabGGT could be a target of the proapoptotic FTI compounds
BMS1, BMS2, and BMS3.
Synergistic effect of compound treatment
with loss of RabGGT
We examined the effect of a low dose of BMS1 (0.3 mM) on
the level of apoptosis caused by a reduction in RabGGT ex-
pression. The experimental rationale is that the effect of a sub-
maximal compound dose will be potentiated if the target’s ac-
tivity is already partially compromised. RNAi directed against
the α subunit of RabGGT (RabGGT-a RNAi) induced a lower
level of germline apoptosis than RNAi directed against the β
subunit (Figure 2B, Table 2E), suggesting that it reduced but
did not eliminate RabGGT activity. Therefore, RabGGT-a RNAi
was used to produce a partial loss of RabGGT function in adult
worms. Table 2E contains data for each treatment administered
individually and in combination with compound. Coadministra-
tion of the RabGGT-a RNAi reagent with BMS1 at 0.3 mM
caused an increase in the level of apoptosis that was substan-
tially greater than the additive value of the independent treat-
ments: the fraction of gonad arms with more than 4 corpses
increased to 88%, from 9% with the RNAi treatment alone or
17% with the low dose of compound alone. No such synergy
was seen between compound treatment and a control RNAi
treatment of an unrelated target that produced a similar level
of apoptosis (Table 2E, Figure 2C). Thus, a specific hypersensi-
tivity to the compound was observed when RabGGT expres-
sion was reduced.
Direct inhibition of RabGGT activity
by the FTI compounds
The synergism of the FTI compounds with RNAi against
RabGGT was suggestive of compound inhibition of RabGGT
activity. We examined this possibility by using an in vitro assay
that reconstituted the prenylation of Rab3A by RabGGT. The
proapoptotic compounds BMS1, BMS2, and BMS3 were found
to be highly potent inhibitors of mammalian RabGGT, with IC50
values of 16–36 nM. Compound BMS4 was up to 33-fold less
potent, with an IC50 of 541 nM. Thus, there was an agreement
between the relative activity of these compounds in apoptosis
assays and their inhibition of RabGGT activity in vitro (Table 1).
Dose response curves differed, which is relevant if it is neces-
sary to completely eliminate the function of RabGGT to pro-
duce apoptosis. For example, compound BMS1 had an IC90
value of 200 nM, whereas BMS4 was 50-fold less potent, withCANCER CELL : APRIL 2005an IC90 of 10 M (Figure 3A and Table 1). BMS1 has been
tested at 8 M or higher on 69 other pharmaceutical targets
with no inhibition of activity, indicating that its action on
RabGGT is specific.
To further investigate the occurrence of dual inhibition and
its relationship to the proapoptotic activity, an additional 19 po-
tent FTI compounds (FT IC50 for H-ras <20 nM) were evaluated
in both assays. The majority of these FTIs were found to also
inhibit RabGGT: 14 compounds had IC50 values below 100 nM,
and the IC50s ranged from 8 nM to >15 M. These observa-
tions further supported a relationship between the potency of
a compound for inhibition of RabGGT (IC90) and its ability to
induce apoptosis (Figure 3B; R2 = 0.76). To extend these ob-
servations, 12 FTIs with a RabGGT IC90 range of 58 to 570 nM
were tested for apoptotic activity across eight further cell lines,
including the p53-negative PC3 and MLF lines. In general, the
compounds induced apoptosis at submicromolar concentra-
tions, with the least potent RabGGT inhibitor also being the
least potent apoptotic agent (Supplemental Table S1; R2 > 0.54
for seven lines). In contrast, no relationship between potency
against FT and apoptotic activity was observed for these com-
pounds (Supplemental Table S1; R2 < 0.23).
To investigate whether cellular activity against RabGGT oc-
curs at doses relevant to the proapoptotic effects of com-
pounds, the A549 human lung cancer cell line was treated with
compounds BMS1 and BMS4. Cellular inhibition of RabGGT
and FT was detected by the cytoplasmic accumulation of un-
prenylated Rab5B or unprenylated H-Ras, respectively. Both
BMS compounds maximally inhibited H-Ras prenylation at the
lowest dose used (Figure 3C). In the same extracts, accumula-
tion of unprenylated Rab5B in BMS1-treated cells was evident
at the 0.5 M dose and increased at the 1M dose, while for
BMS4 no accumulation relative to control treatment was ap-
parent at doses up to 5 M (Figure 3C). To determine whether
apoptosis was induced by these treatments, activation of cas-
pase-3/7 was monitored by the appearance of a luminescent
cleavage product. Staurosporine treatment was included as a
positive control. Caspase activation was induced by BMS1 at
both 0.5 M and 1 M, but was not seen with BMS 4 at doses
up to 5 M (Figure 3D). The observation of a >10-fold differ-
ence between the cellular potency of BMS1 and BMS4 for both
RabGGT inhibition and induction of caspase activity supports
a relationship between these properties. These assays also re-
iterate the lack of relationship between potency against FT and
apoptotic activity for these compounds.
Targeting RabGGT by siRNA induces apoptosis
in mammalian cancer cell lines
If inactivation of RabGGT by compounds BMS1, BMS2, and
BMS3 is a source of their proapoptotic activity in mammalian
cancer cells, then a reduction of RabGGT function by other
means should also induce apoptosis. We induced degradation
of RabGGT mRNA using small interfering RNAs (siRNA), and
examined the effects on apoptotic status of cancer cell lines.
For each RabGGT subunit, two effective siRNAs were selected
(Supplemental Figures S2 and S3). An siRNA targeting the cas-
pase regulator XIAP was also used, providing a benchmark for
induction of apoptosis. siRNAs against both α and β subunits
were antiproliferative (Supplemental Figure S4). Apoptotic
status was evaluated both by measurement of apoptotic indi-329
A R T I C L EFigure 3. Inhibition of RabGGT prenylation activ-
ity by multiple FTIs, and relationship to their
apoptotic activity
A: Representative dose response of RabGGT in-
hibition by BMS compounds. ■, BMS1 (potent in-
hibition);C, BMS4 (weaker inhibition).
B: Levels of apoptotic activity and RabGGT in-
hibitory activity of a series of FTI compounds. The
minimum concentration that produced 50%
apoptosis (EC50) was determined on the HCT-
116 line. Four compounds with an IC90 that ex-
ceeded the assay limit (15 M) are represented
at 15 M. Compounds BMS1–BMS4 are indi-
cated by 6.
C: Western blots of cytoplasmic extracts from
A549 cells treated for 20 hr as indicated. The cy-
toplasmic accumulation of H-Ras (center panel)
and the appearance of Rab5B with decreased
mobility (lower panel, arrow) are diagnostic for
lack of prenylation of newly synthesized protein.
D: Caspase-3/7 activation measured by accu-
mulation of a fluorescent cleavage product in
A549 cells after 23 hr of compound treatment
as indicated (doses are in M). Staurosporine at
300 nM provides a positive control. The average
and standard deviation of replicate assays are
shown.cators in cancer cell populations and by direct observation of
individual cells.
First, activation of caspase-3/7 was monitored by the ap-
pearance of a luminescent cleavage product after siRNAs were
introduced into A549 cells. RabGGT-specific siRNAs produced
significant increases in signal over the background values for
cells transfected with a control siRNA (Figure 4A). The induc-
tion of caspase 3/7 activity by RabGGT siRNAs was compara-
ble to that of the XIAP control, and could be reversed by co-
treatment with the caspase inhibitor Z-VAD-FMK (Figure 4A).
Second, the occurrence of cytoplasmic histone-associated
DNA fragments (a feature of apoptosis; Salgame et al., 1997),
was assayed after the siRNAs were introduced into the A2780
human ovarian carcinoma cell line. The siRNAs to RabGGT
produced a significant signal in this assay, while cells trans-
fected with a control siRNA had the expected background sig-
nal (Figure 4C). Finally, activation of caspase 3, nuclear con-
densation, and proliferation was quantified at two timepoints
in individual cells of the p53 null prostate cancer cell line PC3
(Supplemental Tables S2–S4). Activated caspase 3 was seen
in a substantial proportion of cells; the effect of RabGGT loss
was stronger than that of the positive control XIAP (Figure 4C).
Increased nuclear condensation was seen with siRNAs against
RabGGT and the XIAP control (Figures 4D–4G), with highly
compact nuclei found in caspase-positive cells (Figures 4F and
4G). In summary, the positive results seen for several apoptotic
parameters in three different cell lines demonstrate that a re-
duction in RabGGT function can be sufficient to induce cancer
cell lines to undergo p53-independent apoptosis.330RabGGT mRNA is overexpressed
in a subset of human tumors
Using quantitative reverse transcription-polymerase chain re-
action analysis (qRT-PCR), we measured expression of the
RabGGT-a and -b subunits in 9 different tumor types: breast,
colon, head and neck, kidney, lung, melanoma, ovary, prostate,
and uterine. Matched normal samples were assayed for 169 of
the 194 tumor specimens. We found that both RabGGT-a and
RabGGT-b were expressed abundantly in all tissues examined.
RabGGT-b showed significant overexpression relative to nor-
mal tissue in ovarian tumors, adenocarcinomas of the colon,
large cell lung carcinomas, and melanomas (Kruskal-Wallis
rank statistical analysis with p < 0.05; Figure 5). RabGGT-a
transcripts were also significantly elevated in ovarian tumors
and melanomas (p < 0.05; data not shown).
Discussion
In this work, the nematode C. elegans was used as a surrogate
genetic system to identify the mammalian target responsible
for the proapoptotic activity of a number of compounds that
had been optimized for inhibition of FT. After establishing that
the compounds were also proapoptotic in C. elegans, we
noted a similarity between this compound-induced phenotype
and that produced by RNAi of a class of genes identified in a
genetic screen. This class encodes proteins involved in vesicu-
lar trafficking, and most notably the prenyltransferase RabGGT,
which is responsible for geranylgeranylation of the Rab family
of small GTPases. In worms, the proapoptotic effect of the
compounds is synergistic with a reduction in RabGGT function.
Extending our observations from C. elegans, we demonstratedCANCER CELL : APRIL 2005
A R T I C L EFigure 4. Activation of apoptosis in mammalian
cancer cell lines by siRNA directed against
RabGGT subunits
The median value and range of replicate assays
are shown. Control: siRNA against firefly lucifer-
ase. XIAP, siRNA against the caspase regulator
XIAP. α-2, α-4, siRNAs against RabGGT-a. β-3, β-4:
siRNAs against RabGGT-b.
A: Caspase-3/7 activation measured by accu-
mulation of a fluorescent cleavage product in
A549 cells, 28 hr posttransfection. Inhibition of
activation by Z-FAD-VMK is also shown.
B: Detection of nucleosomal DNA in cytoplasm
of A2780 cells, 48 hr posttransfection.
C: Positive staining for activated caspase 3 in
PC3 cells, 72 and 96 hr posttransfection.
D: Quantification of small or bright nuclei in PC3
cells, 96 hr posttransfection.
E: Nuclei of PC3 cells, 96 hr posttransfection with
the indicated siRNA.
F and G: Staining of PC3 cells, 96 hr posttransfec-
tion with siRNAs against indicated RabGGT sub-
unit. Nuclear DNA is identified with Hoechst
(blue). Cells positive for both activated caspase
3 (rhodamine) and cytochrome C (fluorescein)
appear yellow.that the compounds inhibit mammalian RabGGT activity in vi-
tro and in cells with high potency. Cellular inhibition of Rab
prenylation was evident at doses that induce apoptosis, and
siRNA against RabGGT was sufficient to induce apoptosis in
three human cancer cell lines. Finally, the RabGGT-a and -b
genes are overexpressed in ovarian tumors and melanomas. In
summary, our experimental results illustrate the use of pharma-
cological, biochemical, and genetic methods that have con-
verged upon a single enzyme. These approaches have iden-
tified a novel pathway for p53-independent induction of
apoptosis, and suggest that blocking the posttranslational
modification of Rab proteins is a source of the proapoptotic
activity of some FTIs.
Involvement of the endosomal trafficking
pathway in apoptosis
Regulation of endosomal-lysosomal trafficking emerged as a
common theme from our genetic screens for proapoptotic mu-CANCER CELL : APRIL 2005tations in C. elegans, suggesting a key role for this organelle in
the induction of apoptosis. Endosomal Rab GTPases have very
recently been connected to apoptosis and proliferation of can-
cer cells (Cheng et al., 2004). Our screens identified all known
members of the HOPS complex, which acts with Rab7 to regu-
late endosomal fusion events. We found that knockdown of
the C. elegans Rab GDI also induced high levels of germline
apoptosis, presumably by blocking recycling of GDP-bound
Rab proteins from acceptor vesicle membranes back to donor
membranes (Pfeffer et al., 1995). The apoptotic function of
RabGGT is likely linked to its role in allowing proper membrane
localization of the GTPases Rab5 and Rab7, and possibly other
Rab family members in mammals. Interestingly, the proapopto-
tic effect of the FTI compound L-744,832 has been demon-
strated to require Amphiphysin II (Bin1; DuHadaway et al.,
2003), a protein that functions in endocytosis and is predicted
to interact with small GTPases.331
A R T I C L EFigure 5. RabGGT-β mRNA is overexpressed in colon, lung, skin, and ovar-
ian tumors
RabGGT-β mRNA levels were using qRT-PCR; asterisks indicate differential
expression relative to the corresponding normal tissue (p < 0.05 in the
Kruskal-Wallis rank statistical analysis). Filled box: normal tissue samples.
White box: tumor samples. Circles represent the median, while box bound-
aries represent the interquartile range. Whiskers extend to the observed
values that lie closest to the values calculated by extending the box
boundaries by 1.5 times the interquartile range. Expression values are in
relative quantity units on a linear scale (see Experimental Procedures).
Breast/BAS, basal cell-like; breast/LUM, luminal cell-like; colon/AC, adeno-
carcinoma; colon/nAC, nonadenocarcinoma; lung/AC1 through AC3,
adenocarcinoma subtypes 1 through 3; lung/LCLC, large cell lung carci-
noma; lung/SCC, squamous cell carcinoma; lung/SCLC, small cell lung
carcinoma.How does blocking endosomal-lysosomal trafficking induce
apoptosis? We envision two general models. First, the lyso-
some could act directly on established components of the
pathway. In support of this model, an antisense knockout of
the lysosomal protease cathepsin L lowers Bcl-2 expression
levels and triggers apoptosis in human glioma cell lines (Levi-
car et al., 2003). Similarly, we find that RNAi of the C. elegans
cathepsin L ortholog, cpl-1, induces caspase-dependent
germline apoptosis (data not shown). Alternatively, perturbing
the fusion of endosomes to lysosomes might indirectly induce
apoptosis. In this model, rupture or leakage of accumulated,
unfused vesicles might release proapoptotic agents, such as
ceramide or hydrolytic enzymes, into the cytoplasm.
Identification of novel targets in cancer
The identification of pro- and antiapoptotic target proteins is an
important area of pharmaceutical research (reviewed by Makin,
2002). The work presented in this paper demonstrates that re-
ducing the levels of proteins in the HOPS complex or inhibiting
the prenylation of the key regulatory GTPases Rab5 and Rab7
leads to p53-independent induction of programmed cell death.
p53 is frequently mutated in human tumors, and studies in a
variety of species have indicated that induction of apoptosis
(as opposed to cell cycle regulation) is the most conserved
function of p53 (reviewed by Slee et al., 2004). By screening
for genes whose inactivation triggers apoptosis in the germline332of animals lacking cep-1/p53, we were able to identify potential
drug targets that could have therapeutic benefits in treatment
of p53− tumors.
The enzyme RabGGT presents a chemically tractable new
target for apoptotic induction in cancer cells. We show that
expression of the genes encoding RabGGT subunits is ele-
vated in certain tumor types, indicating that the enzyme may
play a functional role in cancer initiation or progression. The
RabGGT enzyme structure has been determined, and its
mechanism of substrate modification has been studied (Shen
and Seabra, 1996; Thoma et al., 2001a; Thoma et al., 2001b;
Zhang et al., 2000). A recent study that identified structural
factors influencing FTI compound specificity (Reid and Beese,
2004) will provide useful insights for RabGGT inhibitor develop-
ment. Thus, there is an excellent foundation for a rational drug
design approach. Only two compounds that affect RabGGT
activity have previously been described, and neither shows a
high degree of potency or specificity for RabGGT (Ren et al.,
1997; Coxon et al. 2001). Our results demonstrate a strong
link between RabGGT function and apoptosis in human cancer
cells. Interestingly, no broad proliferation or apoptotic effects
were described in mice whose RabGGT-α subunit is impaired
(Detter et al., 2000), suggesting that tumor cells could be hy-
persensitive to the proapoptotic effects of enzyme inhibition.
Deficiencies in RabGGT function have, however, been linked to
blood clotting abnormalities and retinal degeneration (reviewed
by Seabra et al., 2002). The development of specific inhibitors
for RabGGT will facilitate the continued characterization of this
enzyme’s role in apoptosis and other physiological processes.
The role of RabGGT substrates in apoptosis and cancer is
also of interest. Recent data on Rab25 implicates endosome
recycling in development of epithelial cancers (Cheng et al.,
2004). Our genetic screens in worms implicated the endosomal
regulators Rab5 and Rab7 in apoptosis. Rab5 regulates trans-
port from the plasma membrane to early endosomes and en-
dosome-endosome fusion, and has been implicated in growth
control in a number of studies. The Rab5 effector AAPL1 is
essential for cellular proliferation (Miaczynska et al., 2004),
while the tumor suppressor gene TSC2 has been reported to
act as a GAP for Rab5 (Xiao et al., 1997) and overexpression
of the TSC2 GAP domain was found to suppress tumorigenesis
(Jin et al., 1996; Momose et al., 2002). In contrast, overexpres-
sion of PRC17, also a Rab5 GAP, induces tumorigenesis in
nude mice (Pei et al., 2002). Thus, the connection between
GTP cycling by Rab5 and tumorigenesis is not yet clear. Rab7
catalyzes late endosome-lysosome and homotypic (endo-
some-endosome and lysosome-lysosome) fusion. Recently,
Edinger et al. (2003) found that an RNAi against Rab7 slightly
improved the survival of a growth factor-deprived murine cell
line. This discrepancy with the strongly proapoptotic effect of
rab-7 knockdown seen in C. elegans may be due to the dif-
ferent experimental endpoint. It is also possible that despite
the good agreement between C. elegans and mammalian apo-
ptosis assays that is seen for RabGGT, loss of Rab7 would
not induce apoptosis in a mammalian system. Overall, further
studies of Rab5 and Rab7 function in cancer models will be
required to evaluate their utility as targets for cancer therapy.
Implications for specificity of other FTIs
Our data provide the first demonstration of high-potency dual
inhibition of RabGGT and FT. Thoma et al. had raised concernsCANCER CELL : APRIL 2005
A R T I C L Eover FTI specificity upon noting that RabGGT can effectively
bind and transfer farnesyl pyrophosphate (Thoma et al., 2000).
However, since the current generation of FTIs occupy the pep-
tide binding site rather than competing for isoprenoid binding
(see Reid and Beese, 2004), such crossreactivity had seemed
unlikely. Yet the peptide binding site also shows remarkable
structural conservation between the three protein prenyltrans-
ferases (Zhang et al., 2000). Could the ability to crossreact be
a general property of FTIs? Of the 23 FTIs tested in this study,
17 were found to be highly potent inhibitors of RabGGT, indi-
cating that crossreactivity is common but not universal. The 23
compounds have several similarities to clinical candidate FTIs.
They are targeted to the peptide binding site by an imidazole
ring that acts as a ligand for the zinc ion present in all three
enzymes. Imidazole rings have been used for this purpose in
several other FTIs in development, for example in Janssen’s
R115777 (Venet et al., 2003), in Abbott Laboratories’ biphenyl
FTI (Curtin et al., 2003), in the original Merck clinical compound
L-778,123 (Britten et al., 2001), and in Merck’s series of macro-
cyclic compounds (Bell et al., 2002). Additionally, the com-
pounds we tested are predicted to share the common binding
attributes identified by Reid and Beese in their study of six
diverse clinical FTI candidates (Reid and Beese, 2004). This
study also noted that compound selectivity for FT over GGTI
does not depend on the peptide substrate specificity of each
enzyme. Thus, the difference in RabGGT peptide substrate
specificity is not a barrier to crossreactivity by these FTIs. We
have found dual inhibition of FT and RabGGT by multiple com-
pounds with diverse structures, indicating that it is not unusual
for a compound to interact with both proteins. While our data
indicate that the optimization of a compound for inhibition of
FT is not directly linked to potency against RabGGT, it is likely
that additional FTI compounds fortuitously also inhibit RabGGT.
Our data suggest that the role of RabGGT inhibition in the mecha-
nism of action of other proapoptotic FTIs should be evaluated.
Implications for cancer therapy
This work demonstrates that compounds developed as FT in-
hibitors can also be potent inhibitors of RabGGT. These results
have several important implications for the clinical develop-
ment of FTI drugs, which were conceived as specific therapeu-
tics for Ras-related cancers. First, crossreactivity to a second
protein target could explain why FTIs can show activity on tu-
mors and cells that lack transforming Ras function. This discrep-
ancy has provoked research that implicated other FT substrates
such as RhoB (Du et al., 1999a) centromere associated pro-
teins (Ashar et al., 2000), and most recently Rheb (Tee et al.,
2003). Our data show that such research must also consider
activities beyond FT inhibition. Second, our demonstration that
inhibition of RabGGT function is proapoptotic may relate to the
unexpected proapoptotic effects that have been reported for
several FTIs (Du et al., 1999b; End et al., 2001; Jiang et al.,
2000; Rose et al., 2001; Manne et al., 2004). Finally, even low
potency against RabGGT could be relevant in an FTI treatment
setting where high local drug concentrations are achieved.
Thus, our findings may explain and help to manage the dose-
limiting toxicities that have emerged in clinical trials of these
therapeutics (Head and Johnston, 2003). Understanding the
mechanism of action of the FTIs will allow improvements in
patient selection and in monitoring of in vivo efficacy and toxic-CANCER CELL : APRIL 2005ity, and may lead to the development of a new generation of
agents specifically targeting RabGGT.
Chemical genetics is most commonly framed as an open-
ended program to create small molecule modulators of many
different proteins as research tools (Strausberg and Schreiber,
2003). Our work highlights the value of combining genetics and
biochemistry in focused studies to elucidate the in vivo mecha-
nism of single, well-characterized compounds. This approach
may identify novel regulatory mechanisms of important biologi-
cal processes, and also directly assists the development and
clinical use of the resulting drugs. We expect that such studies
will become increasingly important as the standards imposed
on drug selectivity continue to rise, and as the use of pharma-
cogenomic tools to match drug and patient becomes more
common.
Experimental procedures
Compound treatment and phenotypic analysis
of C. elegans
The compounds used in this study (Supplemental Figure S5)
were dissolved in dimethyl sulfoxide (DMSO) and mixed with
dead OP50 bacteria suspended in M9 buffer (Epstein and
Shakes, 1995) at a final DMSO concentration of 4%. This sus-
pension was applied to agar plates, which were then seeded
with 1-day-old adult worms. Apoptosis was quantified at 16
hr with high-resolution Nomarski optics. Corpses were readily
distinguished by their compact, button-like appearance (Gu-
mienny et al., 1999). ced-3(n2433) and ced-4(n1162) were ob-
tained from the CGC.
Genetic mapping, cloning, and sequencing
The ep347 deletion allele of cep-1 was identified by standard
PCR-based methods (Jansen et al., 1997). ep347 removes ex-
ons 9–13 and blocks DNA-damage-induced apoptosis to a
similar extent as mutations in hus-1 and rad-5 (Supplemental
Figure S6). The cep-1 (ep347) allele has this sequence across
the deletion breakpoints: ACATTGATAATGTATCCAGGCGCAG/
CATCCAGGAAGCGATGAAACTGCCA.
Mutagenesis and characterization were according to Epstein
and Shakes (1995). The recessive increased-germline apopto-
sis (Gla) phenotype of the ep402 mutant cosegregated with a
recessive maternal effect lethal (Mel) phenotype. The Mel phe-
notype was mapped relative to single nucleotide polymor-
phisms between CB4586 and N2 (var. Bristol) (detected as de-
scribed by Swan et al., 2002) to a 113 Kb interval between the
regions contained in cosmids Y34B4A and C26B9. RNAi
against the 20 predicted genes in this interval produced a Gla
phenotype for only two: Y34B4A.1 and F32A6.3. Transcript
analysis showed that Y34B4A.1 and F32A6.3 represent a single
gene. ep402 is a nonsense mutation (UGG/ UGA) at codon
523 in predicted exon 9 of F32A6.3.
Treatment of worms with RNAi reagents
RNAi reagents were generated by PCR amplification from a
C. elegans genomic DNA template using LA Taq (Takara).
Gene-specific priming sequences (Supplemental Table S5)
were flanked by the T7 polymerase priming site. Amplicons
typically spanned at least 1 kb and comprised exons. RNA was
transcribed using the MEGAscript High Yield Transcription Kit
(Ambion) and annealed at 68°C for 20 min. PCR product size333
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by gel electrophoresis. dsRNA was precipitated and resus-
pended in 20 mM KPO4, 3 mM potassium citrate, 2% PEG
6000. For RNAi treatment, 1 l of M9 buffer containing w50
L3 worms was added to 3 l of dsRNA (w5 mg/ml) and incu-
bated for 24 hr in a sealed 96-well plate at 20°C, then plated
on NGM plates seeded with OP50 bacteria for 24 hr before
compound treatment and/or apoptosis assays.
Compound inhibition of RabGGT activity
For in vitro analysis, a filter binding assay was modified from
Armstrong et al. (1995) and Shen and Seabra (1996). Reactions
contained 50 mM HEPES (pH 7.4), 5 mM MgCl2, 1 mM DTT, 1
mM NP-40, 2 M human Rab3A (Panvera), 0.2 M human
REP-1 (Calbiochem), 2% DMSO, 10–50 nM rat RabGGT (Cal-
biochem), 5 M unlabeled GPP (Sigma), and 0.5 M labeled
GGPP (Amersham Pharmacia Biotech; 15 Ci/mmol). After 30
min at 37°C, proteins were precipitated and collected onto
GF/A filters (Whatman). Scintillation count data was analyzed
with PRIZM (GraphPad Software, Inc.). For cellular assays,
A549 cells were treated with BMS1 or BMS4 with 20 M
Z-VAD-FMK (Promega). After osmotic lysis, membranes were
pelleted and the cytoplasmic extracts were blotted using anti-
bodies sc-598 and sc-520 (Santa Cruz).
Design and validation of siRNA oligonucleotides
After validation (Supplemental Figures S2–S4), the siRNAs
synthesized (Dharmacon Inc; Reynolds et al., 2004) were α-2
(GCACCUGGCTCACAAGGAU) and α-4 (CGACAGACGAGCA
GCUAUU) (against RabGGT-a), β-3 (GAGAAUGAGUGGCAU
CUAU) and β-4 (UUACUUGGCUGGUGGCUUU) (against Rab
GGT-b), control (AAGGGACGAAGACGAACACUUC; Firefly lu-
ciferase) and D-004098-02 (against XIAP).
Apoptosis assays in mammalian cells
Triplicate samples of cells in RPMI/10% FBS were treated with
compound at the stated doses, or transfected using 20–25 nM
siRNA and 2 g/ml LipofectAMINE 2000 reagent (Invitrogen) in
a final volume of 100 l. Where indicated, Z-VAD-FMK (20 M;
Promega) was included. A549 cells (10,000/well) were processed
with the Apo-one Caspase-3/7 assay (Promega). A2780 cells
(2,000/well) were processed using the Cell Death Detection ELISA
Plus assay (Roche). PC3 cells (2000/well) were fixed with 2%
formaldehyde and stained with Hoechst and antibodies for acti-
vated caspase 3 and cytochrome C (Promega). Arrayscan 4.0
and the Target Activation application (Cellomics Inc.) were used
to analyze 2,000–25,000 cells per treatment. Thresholds were
set 1 standard deviation from median of negative control.
qRT-PCR analysis of mRNA expression
Total RNA was isolated from tissue samples using RNeasy (Qi-
agen), or was obtained from outside sources (Impath Predictive
Oncology, Franklin, MA; Ardais Corporation, Lexington, MA;
Genomics Collaborative, Cambridge, MA; University of Cali-
fornia, Davis, CA). For breast, colon, lung, prostate, and ovary
tumors, 21–33 unique tumor samples were analyzed; for other
tissue types, 11–24 tumor samples were utilized. Preparation
of cDNA and qPCR using SYBR-green was performed with a
7900HT instrument (Applied Biosystems). Data was analyzed
using the application SDS (Applied Biosystems). Expression
levels were normalized to 18S ribosomal RNA. Relative quan-334tity units were calculated from a 5-point standard curve ob-
tained using Universal Human Reference RNA (Stratagene).
Supplemental Data
Supplemental Data are available online at http://www.cancercell.org/cgi/
content/full/7/4/325/DC1/.
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